Early Convalescent Plasma Therapy and Mortality Among US Veterans Hospitalized With Nonsevere COVID-19: An Observational Analysis Emulating a Target Trial.

ABSTRACT:

Background

Early convalescent plasma transfusion may reduce mortality in patients with nonsevere coronavirus disease 2019 (COVID-19).

Methods

This study emulates a (hypothetical) target trial using observational data from a cohort of US veterans admitted to a Department of Veterans Affairs (VA) facility between 1 May and 17 November 2020 with nonsevere COVID-19. The intervention was convalescent plasma initiated within 2 days of eligibility. Thirty-day mortality was compared using cumulative incidence curves, risk differences, and hazard ratios estimated from pooled logistic models with inverse probability weighting to adjust for confounding.

Results

Of 11 269 eligible person-trials contributed by 4755 patients, 402 trials were assigned to the convalescent plasma grou

SUBMITTER: Cho K 

PROVIDER: S-EPMC8411382 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature